1st BMT – Liam’s Chimerism Engraftment Results

Liam received reduced intensity conditioning with Treosulfan and Fludarabine (research Protocol 2256) regimen A.

DAY+ 432 – 07/18/2012        DNA Chimerism Analysis – Blood

 Derived & naive young  T cells       47%

(CD3+) T Cell                       45% donor origin (55% host)

(CD33+) Myeloid Cells           4% donor origin (96% host)

(CD56+) NK Cells               10% donor origin (90% host)

(CD19+) B Cells                       3% donor origin (97% host)

DAY+ 403 – 06/19/2012        DNA Chimerism Analysis – Blood

Derived & naive young  T cells       52%

(CD3+) T Cell                       47% donor origin (53% host)

(CD33+) Myeloid Cells           2% donor origin (98% host)

(CD56+) NK Cells               10% donor origin (90% host)

(CD19+) B Cells                       2% donor origin (98% host)

DAY+ 367 – 05/14/2012        DNA Chimerism Analysis – Blood

Derived & naive young  T cells       53%

(CD3+) T Cell                       50% donor origin (50% host)

(CD33+) Myeloid Cells           4% donor origin (96% host)

(CD56+) NK Cells               14% donor origin (86% host)

(CD19+) B Cells                       5% donor origin (95% host)

DAY+ 341 – 04/2012        DNA Chimerism Analysis – Blood

T-Cell 60% NK Function 10% B-cell 2% they are running another blood test to look closer at the T-cells if that is low then Liam will need a DLI donor boost which would require more blood from Hunter. We should know more on the new tests tomorrow or next week.

Update: Now things r really getting confusing dr left a message that Liam is producing 56% new cells of hunter so he might not need a DLI yet

(CD3+) T Cell                       60% donor origin (40% host)

(CD33+) Myeloid Cells           unknown% donor origin (unknown% host)

(CD56+) NK Cells               10% donor origin (90% host)

(CD19+) B Cells                        2% donor origin (98% host)

04/26/12               DC45RA/CD31 T-cells                   56% donor (44% host)

DAY+ 243 – 01/10/12        DNA Chimerism Analysis – Blood

(CD3+) T Cell                       72% donor origin (28% host)

(CD33+) Myeloid Cells           12% donor origin (88% host)

(CD56+) NK Cells               35% donor origin (65% host)

(CD19+) B Cells                        11% donor origin (89% host)

DAY+ 200 – 11/29/11        DNA Chimerism Analysis – Blood

(CD3+) T Cell                       76% donor origin (24% host)

(CD33+) Myeloid Cells           10% donor origin (90% host)

(CD56+) NK Cells               40% donor origin (60% host)

(CD19+) B Cells                        8% donor origin (92% host)

DAY+ 138 – 09/27/11        DNA Chimerism Analysis – Blood

(CD3+) T Cell                       62% donor origin (38% host)

(CD33+) Myeloid Cells           23% donor origin (77% host)

(CD56+) NK Cells               71% donor origin (29% host)

(CD19+) B Cells                      22% donor origin (78% host)

DAY +80 – 08/05/11        DNA Chimerism Analysis – BMA

(CD3+) T Cell                       62% donor origin (38% host)

(CD33+) Myeloid Cells           54% donor origin (46% host)

(CD56+) NK Cells               89% donor origin (11% host)

(CD19+) B Cells                      57% donor origin (43% host)

DAY +28 – 06/14/11        DNA Chimerism Analysis

(CD3+) T Cell                       59% donor origin (41% host)

(CD33+) Myeloid Cells           100% donor origin (0% host)

(CD56+) NK Cells               100% donor origin (0% host)

(CD19+) B Cells                      100% donor origin (0% host)

The Nuts and Bolts of Bone Marrow Transplants


Bone marrow transplantation (BMT) is a relatively new medical procedure being used to treat diseases once thought incurable. Since its first successful use in 1968, BMTs have been used to treat patients diagnosed with leukemia, aplastic anemia, lymphomas such as Hodgkin’s disease, multiple myeloma, immune deficiency disorders and some solid tumors such as breast and ovarian cancer.

In 1991, more than 7,500 people underwent BMTs nationwide. Although BMTs now save thousands of lives each year, 70 percent of those needing a BMT using donor marrow are unable to have one because a suitable bone marrow donor cannot be found.


[PDF] Reduced-intensity conditioning significantly improves - Blood

File Format: PDF/Adobe Acrobat - Quick View
by RA Marsh - 2010 - Cited by 21 - Related articles
(Blood2010;116(26):5824-5831). Introduction. Familial hemophagocytic lymphohistiocytosis (FHLH) is a collec- tion of primary immune deficiencies

Full Text (PDF) - Blood


by RA Marsh - 2010 - Cited by 21 - Related articles
Published online before print September 20, 2010, doi: 10.1182/blood-2010-04-282392 Blood December 23, 2010 vol.116 no. 26 5824-5831. Show PDF in full

Chimerism analysis is important for monitoring post-transplant outcome and for determining appropriate therapy after transplantation. Since it is the basis for providing early treatment decisions, chimerism analysis requires sensitive and reliable techniques to detect the presence of donor leukocytes in the hosts’ peripheral blood or bone marrow. As lymphoid and myeloid engraftment is asynchronous, lineage-specific chimerism analysis is necessary. This requires the specific enrichment of myeloid and lymphoid cells prior to performing chimerism analysis (e.g. by PCR-based detection of donor- or recipient-specific mini-satellite DNA sequences). http://www.stemcell.com/en/Products/Area-of-Interest/Chimerism.aspx

Chimerism in nonmalignant diseases


Allogeneic stem cell transplantation is the only curative treatment option for many patients with inherited or acquired nonmalignant diseases as thalassemia, sickle cell disease, immunodeficiency diseases, osteopetrosis, storage diseases, severe aplastic anemia, bone marrow failure syndromes and others (for a review, see Section IV in Thomas et al34). The aim of the procedure in these diseases is to achieve sustained engraftment to (i) improve the hematopoietic function, to (ii) correct the immune competence and/or to (iii) increase or normalize the respective enzyme shortage. Therefore a priori, it is not necessary to replace the recipient hematopoietic system completely. The implementation of a state of mixed chimerism is mostly sufficient to substantially improve the patient’s well being. Thus, to reduce toxic side effects, most conditioning regimens are less myeloablative and thereby mixed chimerism is more likely.60,61,62,63 As a consequence, graft rejection or nonengraftment remained the major causes of treatment failures in this diseases. Sensitization to minor histocompatibility antigens by prior blood product transfusion might increase this danger. The rapid development of complete chimerism in NK and T cells seems to play an important role in achieving sustained engraftment especially in patients who were treated with a dose reduced conditioning regimen.64,65,66,67



Pediatric Transplants

Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders



How and when should we monitor chimerism after allogeneic stem cell transplantation?

How and when should we monitor chimerism after allogeneic stem cell transplantation?

P Bader, D Niethammer, A Willasch, H Kreyenberg and T Klingebiel

Source: http://www.nature.com/bmt/journal/v35/n2/full/1704715a.html

Table 1. Chimerism, definition and implications


Next table | Figure and tables index

Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation.

source: http://www.bioportfolio.com/resources/pmarticle/93809/Reduced-intensity-Conditioning-Significantly-Improves-Survival-Of-Patients-With-Hemophagocytic-Lymphohistiocytosis-Undergoing.html


Recent experience suggests that reduced-intensity conditioning (RIC) regimens can improve the outcomes of patients with hemophagocytic lymphohistiocytosis (HLH) undergoing allogeneic hematopoietic cell transplantation (HCT). However, studies directly comparing RIC to myeloablative conditioning (MAC) regimens are lacking. Forty patients with HLH underwent allogeneic HCT between 2003-2009 at Cincinnati Children’s Hospital. Fourteen patients received MAC consisting of busulfan, cyclophosphamide, and anti-thymocyte globulin +/- etoposide. Twenty-six patients received RIC consisting of fludarabine, melphalan, and alemtuzumab. All patients engrafted. Acute GVHD grades II-III occurred in 14% of MAC patients and 8% of RIC patients (p=0.3171). Post-transplant mixed donor/recipient chimerism developed in 18% of MAC patients and 65% of RIC patients (p=0.0110). The majority of patients with mixed chimerism received intervention with reduction of immune suppression +/- donor lymphocyte infusion (DLI) or stem cell boost which stabilized or increased donor contribution to hematopoiesis and prevented relapse of HLH in all but 1 patient. Grade II-III GVHD occurred in 5/14 RIC patients following DLI. The overall estimated 3-year-survival post-HCT was 43% (confidence interval (CI) = +/-26%) for MAC patients and 92% (CI = +/-11%) for RIC patients (p=0.0001). We conclude that RIC significantly improves the outcome of patients with HLH undergoing allogeneic HCT.


Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States;

Journal Details

Name: Blood
ISSN: 1528-0020


MESH Definitions

Transplantation Conditioning

Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.

Conditioning, Eyelid

Reflex closure of the eyelid occurring as a result of classical conditioning.

Physical Conditioning, Animal

Physical conditioning of domestic, laboratory, and zoo animals. Includes exercising of animals.

Graft Survival

The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.

Early Diagnosis

Methods to determine in patients the nature of a disease or disorder at its early stage of progression. Generally, early diagnosis improves PROGNOSIS and TREATMENT OUTCOME.

Reduced-intensity conditioning significantly improves survival of 

www.bioportfolio.com › Latest PubMed Articles › Blood

Forty patients with HLH underwent allogeneic HCT between 2003-2009 at  with reduction of immune suppression +/-donor lymphocyte infusion (DLI) or stem cell  Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced 

Treatment of refractory acute GVHD with third-party MSC expanded 

business.highbeam.com › … › Bone Marrow Transplantation
Feb 1, 2009 – Between March and December 2007, 13 consecutive patients with steroid-refractory  23 days (range 0-49) after the last donor lymphocyte infusion (n=3) or 31 days  (n = 9), infliximab (n = 6), MTX (n = 3) and pentostatin(n=1).  …patients with HLH underwent allogeneic HCT between 2003-2009 at 
Reports on Graft-Versus-Host Disease Findings from Cincinnati Children’s Hospital Provide New Insights.(Report)
Biotech Week; January 26, 2011; 614 words…patients with HLH underwent allogeneic HCT between 2003-2009 at Cincinnati…busulfan, cyclophosphamide, and antithymocyteglobulin plus or minus etoposide…patients with HLH undergoingallogeneic HCT.” Marsh and colleagues published…
New Cell Transplantation Study Results from Cincinnati Children’s Hospital Described.
Biotech Week; October 5, 2011; 552 words…either etoposide orantithymocyte globulin, +/- ciclosporin…genetic forms of HLH isallogeneic HCT. Unfortunately, allogeneic HCT for patients with HLH…patients with HLH with allogeneic HCT, highlighting the important…

Research Results from Children’s Hospital Update Knowledge of Hematology
Hematology Week; September 24, 2012; 613 words…either etoposide or antithymocyte globulin, [+ or -] ciclosporin…genetic forms of HLH is allogeneic HCT. Unfortunately, allogeneic HCT for patients with HLH…patients with HLH with allogeneic HCT, highlighting the important…

New graft-versus-host disease study findings recently were published by researchers at Children’s Hospital.
Blood Weekly; June 25, 2009; 579 words…protocols using TLI andantithymocyte globulin (ATG), followed by allogeneic…expansion to regulate GVHD after allogeneic HCT. (Blood. 2009; 113…United States, Memphis, Antithymocyte globulin, Bone Marrow Transplantation…

New findings reported from University of Pittsburgh describe advances in sickle cell anemia.(Clinical report)
Blood Weekly; January 1, 2009; 618 words…busulfan, fludarabine, equine antithymocyte globulin, and total lymphoid irradiation…the curative potential of allogeneic HCT after an RIC regimen in…Antimetabolite, Antineoplastic, Antithymocyte globulin, Bone Marrow, Busulfan…

New lymphoproliferative disorders study results reported from National Institutes of Health.
Blood Weekly; July 2, 2009; 599 words…depletion of the donor marrow, antithymocyte globulin (ATG) use, and unrelated…of patients who underwent allogeneic HCT at elevated risk of PTLDs…Lymphoproliferative Disorders, Antithymocyte globulin, Cell Transplantation…

Leave a Reply